Osimertinib: A Game-Changer in Stage IV EGFR-Driven Lung Cancer

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Advanced non-small cell lung carcinoma (NSCLC) has a high mortality rate, but targeted therapies have improved survival.
• Epidermal growth factor receptor (EGFR) mutations occur in about 15% of NSCLC cases.
• Osimertinib is an EGFR tyrosine kinase inhibitor approved for first-line treatment of advanced NSCLC with EGFR sensitizing mutations.

Purpose of the Study:

• To report a case of advanced NSCLC with an EGFR exon 19 deletion treated with first-line osimertinib.
• To highlight the achievement of a complete metabolic response and significant clinical improvement in a patient with extensive metastatic disease.

Main Methods:

• A 55-year-old male former smoker with a six-month history of worsening cough and dyspnea was diagnosed with lung adenocarcinoma.
• Diagnosis was confirmed by bronchial biopsy showing EGFR exon 19 deletion.
• Staging revealed Stage IV-A disease with pulmonary and adrenal metastases; treatment initiated with first-line osimertinib.

Main Results:

• The patient achieved a complete metabolic response on PET-CT five months after starting osimertinib.
• Significant clinical improvement was observed, with the patient resuming physical activity and achieving a performance status of 0.
• Despite extensive thoracic disease, osimertinib demonstrated high efficacy in this patient.

Conclusions:

• Osimertinib can induce remarkable responses, including complete metabolic response, in patients with advanced NSCLC and EGFR mutations.
• This case underscores the efficacy of EGFR tyrosine kinase inhibitors but also raises questions regarding treatment duration and monitoring.
• Further research is needed to understand factors influencing rare complete responses and the role of circulating tumor DNA.